Filing Flows › Myriad Genetics (MYGN) › Q4 2025
Myriad Genetics (MYGN) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
Myriad Genetics (MYGN) reported revenue of $210M for the fourth quarter 2025 (Q4 2025), -0.4% from a year earlier and +2% from the quarter before. Operating margin was -2.7%, net loss $7.9M (3.8% of revenue).
Myriad Genetics, Q4 2025: revenue $210M (-0.4% year over year), operating margin -2.7%, net loss $7.9M, operating cash flow $10.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $210M | +2% | -0.4% |
| Operating profit | −$5.7M | — | — |
| Net earnings | −$7.9M | — | — |
| Operating cash flow | $10.6M | -50% | +61% |
| Free cash flow | $5.9M | — | +97% |
What changed
Revenue was $209.8M in Q4 2025, roughly flat year over year and up 2% from the previous quarter.
Gross margin was 70.0%, down 1.7 points from a year earlier. Operating costs exceeded revenue by $5.7M, an operating margin of -2.7%. Operating expenses fell 20% while revenue was flat. The quarter ended with a net loss of $7.9M, narrower than the previous quarter's $27.4M loss.
Operating cash flow was $10.6M (up 61% year over year). Non-cash charges added back $12.6M of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items added $3.1M. Capital expenditures of $4.7M left free cash flow of $5.9M.
Questions
What was Myriad Genetics' revenue in the fourth quarter 2025?
Myriad Genetics (MYGN) reported revenue of $210M for the fourth quarter 2025 (Q4 2025), -0.4% from a year earlier and +2% from the quarter before.
Was Myriad Genetics profitable in the fourth quarter 2025?
Operating loss was $5.7M (-2.7% of revenue) and net loss $7.9M.
Source: Myriad Genetics 10-K on SEC EDGAR.